Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 18/20 | 0.51 |
| ▸ | TNF | P01375 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2417308 | 1.00 | TLR2 (0.51) | TLR2TNF | |
| SCHEMBL2424676 | 1.00 | TLR2 (0.51) | TLR2TNF | |
| SCHEMBL173805 | 1.00 | TLR2 (0.51) | TLR2TNF | |
| SCHEMBL15768591 | 1.00 | TLR2 (0.51) | TLR2TNF | |
| SCHEMBL2453440 | 1.00 | TLR2 (0.51) | TLR2TNF | |
| SCHEMBL14762537 | 0.94 | TLR2 (0.55) | TLR2TNF | |
| SCHEMBL14762587 | 0.91 | TLR2 (0.56) | TLR2TNF | |
| SCHEMBL2453889 | 0.91 | TLR2 (0.56) | TLR2TNF | |
| SCHEMBL2451299 | 0.91 | TLR2 (0.56) | TLR2TNF | |
| SCHEMBL2418982 | 0.91 | TLR2 (0.56) | TLR2TNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11458212-B2 | Molecular imaging of cancer cells in vivo | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2022-10-04 | — | — | US | disclosed |
| US-20200164093-A1 | Molecular Imaging of Cancer Cells In Vivo | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2020-05-28 | — | — | US | disclosed |
| US-10406248-B2 | Molecular imaging of cancer cells in vivo | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2019-09-10 | — | — | US | disclosed |
| US-20140161725-A1 | Molecular Imaging of Cancer Cells In Vivo | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2014-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140161725-A1 | Molecular Imaging of Cancer Cells In Vivo | MKI67, ANXA4, ANXA3 | TLR2 3203/4885TNF 4821/4885 |
| US-11458212-B2 | Molecular imaging of cancer cells in vivo | MKI67, ANXA4, ANXA3 | TLR2 3203/4885TNF 4821/4885 |
| US-10406248-B2 | Molecular imaging of cancer cells in vivo | MKI67, ANXA4, ANXA3 | TLR2 3203/4885TNF 4821/4885 |
| US-20200164093-A1 | Molecular Imaging of Cancer Cells In Vivo | MKI67, ANXA4, ANXA3 | TLR2 3203/4885TNF 4821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.